Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes

References

• BRIAN, W. R., SRIVASTAVA, P. K., UMBENHAUER, D. R., LLOYD, R. S. and GUENGERICH, F. P., 1989, Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry, 28, 4993–4999.
   PubMed Web of Science ®Google Scholar
• DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., MEYER, U. A., NAKAMURA, K. and GOLDSTEIN, J. A., 1994, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594–598.
   Google Scholar
• GOLDSTEIN, J. A. and DE MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285–299.
   PubMedGoogle Scholar
• GONZALEZ, F. J., 1989, The molecular biology of cytochrome P450s. Pharmacological Reviews, 40, 243–288.
   Web of Science ®Google Scholar
• GONZALEZ, F. J., CRFSPI, C. L. and GELBOIN, H. V., 1991, cDNA-expressed human cytochrome P450s : a new age of molecular toxicology and human risk assessment. Mutation Research, 247, 113–127.
   PubMed Web of Science ®Google Scholar
• GONZALEZ, F. J. and KORZEKWA, K. R., 1995, Cytochromes P450 expression systems. Annual Reviews of Pharmacology and Toxicology, 35, 369–390.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1991, Reactions and significance of cytochrome P-450 enzymes. Journal of Biological Chemistry, 266, 10019–10022.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1994, Analysis and characterization of enzymes. In Principles and Methods of Toxicology, edited by A. W. Hayes (New York: Raven), pp. 1259–1313.
   Google Scholar
• GUENGERICH, F. P., BRIAN, W. R., SARI, M.-A. and Ross, J. T., 1991, Expression of mammalian cytochrome P450 enzymes using yeast-based vectors. Methods in Enzymology, 206, 130–145.
   Google Scholar
• GUENGERICH, F. P., GILLAM, E. M. J. and SHIMADA, T., 1996, New applications of bacterial systems to problems in toxicology. Critical Reviews in Toxicology, 26, 551–583.
   Google Scholar
• GUENGERICH, F. P. and SHIMADA, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391–407.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., WANG, P. and DAVIDSON, N. K., 1982, Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry, 21, 1698–1706.
   PubMed Web of Science ®Google Scholar
• HAINING, R. L., HUNTER, A. P., VER0NEsE, M. E., TRAGER, W. F. and RETTlE, A. E., 1996, Allelic variants of human cytochrome P4502C9: baculovirus-mediated expression, purification, struc-tural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Archives of Biochemistry and Biophysics, 333, 447–458.
   Google Scholar
• INOUE, K., YAMAZAKI, H., ImIYA, K., AKASAKA, S., GUENGERICH, F. P. and SHIMADA, T., 1997, Relationship between CY P2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetks, 7, 103–113.
   PubMedGoogle Scholar
• KAMINSKY, L. S., FASCO, M. J. and GUENGERICH, F. P., 1981, Production and application of antibodies to rat liver cytochrome P-450. Methods in Enzymology, 74, 262–272.
   PubMedGoogle Scholar
• KAMINSKY, L. S., DE MORAIS, S. M. F., FALETTO, M. B., DUNBAR, D. A. and GOLDSTEIN, J. A., 1993, Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Molecular Pharmacology, 43, 234–239.
   Google Scholar
• KNODELL, R. G., HALL, S. D., WILKINSON, G. R. and GUENGERICH, F. P., 1987, Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. Journal of Pharmacology and Experimental Therapeutics, 241, 1112–1119.
   PubMed Web of Science ®Google Scholar
• LANG, D. and BöcKER, R., 1995, Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. Journal of Chromatography B: Biomedical Applications, 672, 305–309.
   Google Scholar
• LOPEZ-GARCIA, M. P., DANSETTE, P. M., VALADON, P., AMAR, C., BEAUNE, P. H., GUENGERICH, F. P. and MANSUY, D., 1993, Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. European Journal of Biochemistry, 213, 223–232.
   Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MIMURA, M., BABA, T., YAMAZAKI, H., OHMORI, S., INUI, Y., GONZALEZ, F. J., GUENGERICH, F. P. and SHIMADA, T., 1993, Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metabolism and Disposition, 21, 1048–1056.
   PubMed Web of Science ®Google Scholar
• NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS I. C. and NEBERT D. W., 1996, P450 superfamily : update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1–42.
   Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• RETTlE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. C., AOYAMA, T., GELBOIN H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chemical Research in Toxicology, 5, 54–59.
   Google Scholar
• RETTIE, A. E., WlENICERS, L. C., GONZALEZ, F. J., TRAGER, W. F. and KORZEKWA, K. R., 1994, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39–42.
   PubMedGoogle Scholar
• ROMKES, M., FALETTO, M. B., BLAISDELL, J. A., RAUCY, J. L. and GOLDSTEIN, J. A., 1991, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450I1C subfamily. Biochemistry, 30, 3247–3255.
   PubMed Web of Science ®Google Scholar
• SANDHU, P., BABA, T. and GUENGERICH, F. P., 1993, Expression of modified human cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Archives of Biochemistry and Biophysics, 306, 443–450.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., IWASAKI, M., MARTIN, M. V. and GUENGERICH, F. P., 1989, Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002. Cancer Research, 49, 3218–3228.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., MISONO, K. S. and GUENGERICH, F. P., 1986, Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. Journal of Biological Chemistry, 261, 909–921.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SPIELBERG, S., MCCREA, J., CRIBB, A., RUSHMORE, T., WALDMAN, S., BJOMSSON, T., Lo, M.-W. and GOLDBERG, M., 1996, A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clinical Pharmacology and Therapeutics, 59, 215.
   Google Scholar
• SULLIVAN -KLOSE, T. H., GHANAYEM, B. I., BELL, D. A., ZHANG, Z. Y., KAMINSKY, L. S., SHENFIELD G. M., MINERS, J. O., BIRKETT, D. J. and GOLDSTEIN, J. A., 1996, The role of the CYP2C9-Leu3"' allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341–349.
   Google Scholar
• TRACY, T. S., ROSENBLUTH, B. W., WRIGHTON, S. A., GONZALEZ, F. J. and KORZEKWA, K. R.,1995, Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Biochemical Pharmacology, 49, 1269–1275.
   PubMed Web of Science ®Google Scholar
• VERONESE, M. E., DOECKE, C. J., MACICENZ1E, P. I., MuMANus, M. E., MINERS, J. O., REES, D. L., GASSER, R., MEYER, U. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal, 289, 533–538.
   Google Scholar
• WANG, S. L., HUANG, J. D., LAI, M. D. and TSAI, J. J., 1995, Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 5, 37–42.
   PubMedGoogle Scholar
• YAMAZAKI, H., Guo, Z., PERSMARK, M., MEVIURA, M., INOUE, K., GUENGERICH, F. P. and SHIMADA, T., 1994, Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Molecular Pharmacology, 46, 568–577.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INouE, K., TURVEY, C. G., GUENGERICH, F. P. and SHIMADA, T., 1997, Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metabolism and Disposition, 25, 168–174.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., NAKANO, M., IMAI, Y., UENG, Y.-F., GUENGERICH, F. P. and SHIMADA, T., 1996, Roles of cytochrome b., in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Archives of Biochemistry and Biophysics, 325, 174–182.
   Google Scholar
• YASUMORI, T., YAMAZOE, Y. and KATO, R., 1991, Cytochrome P-450 human-2 (P-450I1C9) in mephenytoin hydroxylation polymorphism in human livers: differences in substrate and stereoselectivities among microheterogeneous P-45011C species expressed in yeasts. Journal of Biochemistry, 109, 711–717.
   PubMed Web of Science ®Google Scholar
• ZHANG, Z., FASCO, M. J., HUANG, Z., GUENGERICH, F. P. and KAMINSKY, L. S., 1995, Human cytochromes P4501A1 and P4501A2 : R-warfarin metabolism as a probe. Drug Metabolism and Disposition, 23, 1339–1345.
   PubMed Web of Science ®Google Scholar